Author: Aspire Biopharma Holdings, Inc.

Convenient Size at the Convenience Store

ESTERO, FL / ACCESS Newswire / March 10, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire”), today announced that its subsidiary, Buzz Bomb Caffeine Company, is expanding its retail footprint with the launch of the BUZZ BOMB^™ Convenience Store Pack.

Convenience stores are where many of today’s quick decisions happen, and the checkout counter plays a big role in those moments. By introducing BUZZ BOMB^™ into that space, we are giving the consumer greater choice and making BUZZ BOMB^™ easier to enjoy and more accessible. This expansion is part of Buzz Bomb Caffeine Company’s broader strategy to evolve with people’s needs, energize convenience retail and drive growth across the caffeine category.

The Lineup

The lineup includes the newly designed six-count “Fruit Blast” package containing two each of the following flavors: Tropical Fruit, Mixed Berry, and Peach Mango, allowing for packaging options that fit changing habits.

BUZZ BOMB^™ Convenience Store Pack

The Caffeine Evolution: No Liquid, No Limits
BUZZ BOMB^™ is a fast-acting dry powder delivered in a single-serving stick pack designed to be sprinkled directly under the tongue. Unlike traditional energy drinks or pills, this serving method allows for a rapid caffeine boost without the need for water, mixing, or consuming large volumes of liquid.

Key Product Highlights:

• Precision Dosing: Each stick pack delivers 50mg serving of caffeine.

• Ultimate Portability: Slim, light, single-serving packs fit easily into pockets, gym bags, or car consoles.

• Six pack “Fruit Blast” Offering: Featuring two each of the following flavors: Tropical Fruit, Mixed Berry, and Peach Mango.

• Clean Energy: Ideal for athletes, professionals, and students seeking a quick, affordable alternative to coffee or soda.

“We are redefining how the world consumes caffeine,” said Kraig Higginson, Interim CEO of Aspire Biopharma. “By moving into the convenience store sector, we are meeting our customers exactly where they need us-on the go, providing a precise, flavored caffeine hit that we believe works faster than a beverage.”

The BUZZ BOMB^™ Convenience Store Packs will begin appearing on shelves in select locations starting in May.

BUZZ BOMB^™ Caffeine Products

Unlike traditional energy drinks or pills, BUZZ BOMB^™ is a new and exciting caffeine product delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method provides flavored caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee, or soda.

BUZZ BOMB^™ features 50mg of caffeine and is currently offered in four delicious flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB^™ provides a precise serving of caffeine in easy-to-use single serving stick packs.

To learn more about BUZZ BOMB^™, or purchase product online, please visit https://buzzbombcaffeine.com or follows us on social media here:

Facebook
Instagram
TikTok

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma delivers supplements to the body rapidly and precisely.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication.

Phase 1 clinical trial of the patent-pending, rapid-onset formulation planned for mid-2026.

Alprazolam remains a top 40 prescribed medication in the US, with over 15.8 million prescriptions in 2023.

ESTERO, FL / ACCESS Newswire / March 3, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a biopharmaceutical company developing multi-faceted, patent-pending drug delivery technology, today announced a strategic partnership with Microsize (Quakertown, Pennsylvania), the largest independent North American contract development and manufacturing organization (CDMO) focused on cGMP micronization and particle size engineering.

Aspire has engaged Microsize to accelerate the development of a novel sublingual powder formulation of alprazolam, the active pharmaceutical ingredient (API) in the widely prescribed anti-anxiety medication Xanax^®.

Addressing the Need for Faster Relief
Although traditional oral alprazolam tablets are highly effective, they can take 25 minutes or more to take effect as they pass through the gastric system and liver. Aspire’s novel sublingual formulation is designed to bypass the digestive tract, delivering the medication directly into the bloodstream for faster, more predictable relief of anxiety disorders and panic attacks.

“Our collaboration with Microsize is a critical milestone in bringing a modern, fast-acting alternative to millions of patients suffering from anxiety” said Kraig Higginson, Interim CEO of Aspire Biopharma. “Microsize’s unparalleled expertise in particle engineering, together with the support of Pace®, a leading testing and analytical lab, will allow us to optimize our sublingual powder, accelerating our journey toward a Phase 1 clinical trial planned for mid-2026. We are aiming to be the first alprazolam sublingual product on the market.”

Industry-Leading Technical Collaboration
Microsize specializes in particle size reduction, micronization, and solubility enhancement for drugs. To complement this development, Aspire has also engaged Pace®, a leading science and technology company with a nationwide network of laboratories, to manage drug-excipient compatibility, formulation development, batch manufacturing, and stability studies.

Market Opportunity
Alprazolam was the 37th most commonly prescribed medication in the United States in 2023, with over 15.8 million combined branded and generic prescriptions. According to Research and Markets, the global alprazolam powder market is projected to reach $55.84 billion by 2032, driven by increasing prevalence of anxiety, a growing geriatric population, and the demand for enhanced drug delivery systems.

About Microsize
For over 30 years, Microsize has been a pioneer in enhancing dissolution and bioavailabilty of Active Pharmaceutical Ingredients (API’s) and functional excipients via particle size reduction technologies including milling, micronization and classification. Operating from 100,000 square feet in US-based, state-of-the-art, FDA inspected GMP facilities, Microsize has the experience and capabilities to rapidly develop, scale up, and process API’s and excipients ranging from grams to multi-metric tons, including highly potent compounds. Microsize is the partner of choice from small biotechs to big pharma to CDMO’s, and is recognized for its speed, responsiveness, and high customer-touch business model. Visit www.microsize.com.

About Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning small molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

BUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson’s historic record at the Jackpot Ultra Running Festival.

ESTERO, FL / ACCESS Newswire / February 25, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), today announced a massive expansion of its social media and digital marketing footprint for its wholly owned subsidiary, Buzz Bomb Caffeine Company. The initiative follows a successful strategic rebranding and a high-profile sponsorship of professional ultra-marathoner Ashley Paulson, whose recent world-record performance catalyzed a significant increase in brand visibility and consumer acquisition.

BUZZ BOMB™-a caffeine supplement delivering a precise 50mg serving in convenient and flavorful stick packs-has seen its social media content surpass 400,000 views in a 48-hour period after the race. This digital momentum coincides with the brand’s recent evolution, featuring a sleek modern website and science-forward packaging designed to appeal to high-performance athletes and everyday consumers alike.

The brand’s visibility reached a fever pitch at the 2026 Jackpot Ultra Running Festival. BUZZ BOMB™ Brand Ambassador Ashley Paulson set a new women’s world record during the USATF 100-Mile Road Championship, winning the event by over two hours with a staggering time of 12:19:34 (breaking the old record by more than 20 minutes). Competing in her signature pink ponytail and BUZZ BOMB™ gear, Paulson credited her use of BUZZ BOMB™ caffeine supplements for helping her maintain her 7:21 per mile pace throughout the 100-mile race. Ashley’s accomplishments were highlighted in Runner’s World and on the US Track and Field web sites. Runner’s World featured an article about Ashley’s record.

“We are thrilled that our brand ambassador, Ashley Paulson, achieved a first-place finish for women at the Jackpot Ultra Running Festival,” said Kraig Higginson, Interim CEO of Aspire Biopharma. “We didn’t just want a face for the brand; we wanted an elite athlete who relies on our caffeine products to perform at the highest level possible. Ashley’s world record-breaking win supports our belief that BUZZ BOMB™ is the ultimate tool for sustained performance.”

Buzz Bomb Caffeine Company team members were there to cheer Ashley and in a post-race interview with her sponsor, she said, “Honestly, it doesn’t feel real. I’m like, has this really happened? … I worked so hard for it, but it came, it happened. Dreams come true, you just got to keep fighting for it and show up, put in the work, and then execute.”

For more about Ashley Paulson, follow her on Instagram, TikTok and Facebook.

https://www.instagram.com/ashkickn/?hl=en,

https://www.tiktok.com/@ashkickn1

https://www.facebook.com/ashley.j.paulson/

BUZZ BOMB™ Caffeine Products

Unlike traditional energy drinks or pills, BUZZ BOMB™ is a new and exciting caffeine product delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method provides flavored caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee, or soda.

BUZZ BOMB™ features 50mg of caffeine and is currently offered in four delicious flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise serving of caffeine in easy-to-use single serving stick packs.

To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com or follows us on social media here:

Facebook

Instagram

TikTok

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma delivers supplements to the body rapidly and precisely.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

New independent director Phillip Balatsos brings commercial and capital markets expertise to drive development patent-pending drug delivery platform

ESTERO, FL / ACCESS Newswire / February 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the appointment of Phillip Balatsos to its Board of Directors, effective February 6, 2026. The appointment follows the planned departures of Suren Ajjarapu and Donald G. Fell, from the board.

“On behalf of our Board, I am delighted to welcome Phillip to the Aspire Biopharma Board. His leadership experience will provide invaluable guidance as the organization continues to evolve and strengthen,” said Kraig Higginson, Interim CEO and Chairperson of the Aspire Biopharma Board. “We are confident that his insights will help accelerate our strategy of reformulating established drugs with large markets and reinforce the Company’s commitment to patients, customers, and shareholders.”

Phillip Balatsos is a senior financial markets executive and board director with over 25 years of experience across foreign exchange, emerging markets, institutional sales and trading, and public company governance. He has held leadership roles at global financial institutions including Barclays Capital, Credit Suisse, and XP Investments, and currently operates within an independent trading platform at Oscar Gruss & Son.

In addition to his capital markets career, Mr. Balatsos brings entrepreneurial and operating experience, having founded and scaled a multi-location hospitality business and advised national restaurant groups on procurement, pricing, and operational efficiency. This background provides a pragmatic operator’s perspective on margins, cost structures, and execution-particularly valuable in growth and turnaround environments.

Mr. Balatsos currently serves on the Boards of Directors of Inspire Veterinary Partners, Inc., where he is a member of the Audit Committee, and Ciso Global, Inc., a cybersecurity and risk management company. He previously served on the Board of Sadot Group Inc., contributing to its transformation from a restaurant operator into a global agri-commodity trading and food supply chain business, and serving on both the Audit and Executive Compensation Committees.

He holds a Bachelor of Science in Business Administration from Skidmore College, with a minor in International Relations and a concentration in Spanish.

Phillip Balatsos will serve on the Audit and Compensation Committees.

“The Company’s mission to provide rapid-onset therapeutics through novel sublingual formulations resonates strongly with my experience in scaling growth-stage companies,” said Mr. Balatsos. “I look forward to supporting this team as they advance their platform and drive the next phase of growth and innovation.”

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events an developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicines

Ondansetron, currently sold under the brand name Zofran^®, was the 53rd most commonly prescribed medication in the U.S. in 2023

Global ondansetron market size valued at approximately $1.4 billion in 2023

ESTERO, FL / ACCESS Newswire / February 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO). The application, titled “A Sublingual Powder Formulation of Ondansetron and Methods of Use Thereof,” marks the first-ever sublingual powder delivery system for ondansetron-the active ingredient in Zofran^®. Aspire’s formulation is designed to provide rapid relief for patients suffering from nausea and vomiting induced by chemotherapy, radiation, or surgery.

Redefining Nausea Relief: IV Speed Without the Needle

Ondansetron is currently limited by a roughly 30-minute delay when taken as a tablet. NIH

Aspire’s sublingual platform is engineered to deliver:

• Near-Instant Absorption: Bypasses the gastrointestinal tract and first-pass metabolism, potentially reducing onset of action from 30 minutes to just minutes.

• Clinical Comparability: Designed to mirror the speed of intravenous (IV) administration without the need for hospital-based injections or professional assistance.

• Patient Compliance: Specifically addresses the “unmet need” for patients who cannot swallow tablets due to severe emesis (vomiting) or gastric irritation.

Strategic Market Positioning

• Significant and Growing Utilization: Ondansetron was the 53rd most prescribed medication in the U.S. in 2023, with over 12.5 million prescriptions, according to ClinCalc.

• Market Growth: The global ondansetron market is projected to grow from $1.4 billion (2023) to $2.4 billion by 2032, driven by rising cancer incidences and expanded surgical procedures, according to DATAINTELO.

• Accelerated Approval Path: Aspire intends to utilize the FDA’s 505(b)(2) regulatory pathway, which leverages existing safety data to streamline clinical development and reduce time-to-market.

CEO Commentary

“This product candidate exemplifies the real-world clinical benefits of our sublingual drug delivery technology, providing fast relief when minutes matter most. By making existing, trusted medications work better and faster, we aim to provide a treatment solution for anyone facing the debilitating effects of acute nausea-from chemotherapy side effects to post-operative recovery,” said Kraig Higginson, Interim CEO of Aspire.

About Zofran^® and Ondansetron
Zofran^®, developed by GlaxoSmithKline, was approved by the FDA in 1991, with a generic version approved in July 2007. Ondansetron is used to prevent nausea and vomiting that is caused by cancer medicines (chemotherapy) or radiation therapy. It is also used to prevent nausea and vomiting that may occur after surgery. Ondansetron works in the stomach to block the signals to the brain that cause nausea and vomiting.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events an developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

ESTERO, FLORIDA / ACCESS Newswire / February 11, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that it has entered into a securities purchase agreement on February 6, 2026 (the “Securities Purchase Agreement”) with select institutional and accredited investors (collectively, the “Investors”) for the purchase and sale of up to 26,250 shares of Series A Convertible Preferred Stock (each, a “Preferred Share” and collectively, the “Preferred Shares”), at a purchase price of $800 per Preferred Share. The Preferred Shares are convertible into shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), representing aggregate gross proceeds to the Company of up to $21.0 million, before deducting placement agent fees and other offering expenses (the “Offering”).

Concurrently with the execution of the Securities Purchase Agreement, the Company completed the initial closing (the “Initial Closing”) of the Offering on February 6, 2026, issuing an aggregate of 13,750 Preferred Shares for gross proceeds of $11.0 million, before deducting placement agent fees and other offering expenses and amounts used for the repayment of certain legacy indebtedness. In accordance with the Securities Purchase Agreement, a portion of the proceeds from the initial closing will be used to support the Company’s legacy business operations, fund strategic initiatives and pay offering-related expenses. The second closing of the Offering is expected to occur at a later date and remains subject to the satisfaction of customary closing conditions and the other conditions set forth in the Securities Purchase Agreement, which has been filed with the Securities and Exchange Commission (the “SEC’). Additional information regarding the Offering is available in the Company’s Current Report on Form 8-K filed on February 11, 2026 with the SEC.

The Offering is expected to enable the Company to regain compliance with Nasdaq’s stockholders’ equity listing requirements, representing an important milestone in the Company’s ongoing balance sheet restructuring and positioning the Company to support the continued development of its patent-pending drug delivery technologies.

Following the Initial Closing, the Company expects to significantly reduce its outstanding indebtedness and further strengthen its balance sheet, enhancing financial flexibility and providing additional resources to advance its clinical and development initiatives while supporting long-term shareholder value.

RBW Capital Partners LLC, whose securities and brokerage services are offered through Dawson James Securities, Inc., acted as sole placement agent for the private placement.

The securities being offered and sold by the Company in the Offering have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file one or more registration statements with the SEC covering the resale of the unregistered shares issuable upon the conversion of the Preferred Shares.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events an developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed

ESTERO, FLORIDA / ACCESS Newswire / February 10, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Company remains subject to an extension to evidence compliance with the $2.5 million stockholders’ equity requirement.

The Company has made meaningful progress on its strategic plans for 2026 and expects to share additional details in the coming weeks. The Company believes that regaining compliance with this listing requirement positions it well for 2026.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events an developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

ESTERO, FL / ACCESS Newswire / February 3, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), wholly owned subsidiary, Buzz Bomb Caffeine Company, today announced a strategic brand management and distribution agreement with Blue Shark Beverages. Effective February 1, the relationship is expected to drive the retail expansion of BUZZ BOMB™, a proprietary 50mg sublingual caffeine stick pack in four flavors, across key Southern California markets.

The rollout will debut in Palm Springs and surrounding cities in the Coachella Valley, followed by a phased expansion into the Los Angeles and San Diego metropolitan areas.

Blue Shark Beverages, a family-owned independent distributor, services retail channels throughout Southern California. By leveraging Blue Shark’s established network, BUZZ BOMB™ aims to capture the growing “better-for-you” energy market with its portable, fast-acting caffeine product.

“We are thrilled to bring BUZZ BOMB™ to the premier resorts, hotels, and casinos of Palm Springs and the Coachella Valley,” said Kara Topolsky, Founder and CEO of Blue Shark Beverage. “As the first to introduce this innovative sublingual energy supplement to our local market, we are especially excited for its debut at the upcoming Coachella and Stagecoach Festivals. Festival weekends are a marathon and BUZZ BOMB™ is the ultimate companion for fans who need instant energy to keep the celebration going.”

“The demand for functional, health-conscious fitness supplements is accelerating as consumers pivot away from traditional sugary energy drinks and stomach-aggravating sodas,” said Kraig Higginson, Interim CEO of Aspire. “Blue Shark Beverages has a proven track record of scaling emerging brands through superior service and deep regional expertise. This collaboration is a pivotal first step in our 2026 strategy to increase placement of our BUZZ BOMB™ product where our customers live, work and play, through a diversity of channels and geographic locations.”

BUZZ BOMB™ Caffeine and Sublingual Delivery

According to Grandview Research , the global energy drinks market size was estimated at $79.39 billion in 2024 and is projected to reach $125.11 billion by 2030, growing at a CAGR of 8.0% from 2025 to 2030. Energy drinks have become increasingly popular among fitness enthusiasts and athletes due to their ability to provide a quick energy boost.

Unlike traditional energy drinks, coffee, or soda, BUZZ BOMB™ utilizes a proprietary sublingual format delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method delivers pure caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee, or soda.

BUZZ BOMB™ features 50mg of caffeine and is currently offered in four flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise amount of caffeine with the convenience of single-serving stick pack.

To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a sublingual delivery method that can deliver supplements to the body rapidly and precisely.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire